<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793649</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-234-0103</org_study_id>
    <nct_id>NCT01793649</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether
      GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared
      to vehicle of 2.8% saline alone.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of MCC from Whole Lung Compartment</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary endpoint of this study will be the calculated area under the curve of MCC from the whole lung compartment, assessed through 60 minutes post isotope dosing (AUC-60min), which will provide a description of the MCC curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of MCC from Central and Peripheral Lung</measure>
    <time_frame>4 weeks or duration of study</time_frame>
    <description>This outcome measure will be the calculated area under the cuve of MCC from the central and peripheral lung assessed through 60 minutes post isotope dosing (AUC60min).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability of GS-5737</measure>
    <time_frame>4 weeks or duration of study</time_frame>
    <description>Adverse events, airway reactivity, pulse oximetry, physical examination, and clinical laboratory test findings, urine and plasma potassium levels, 12-lead ECG abnormalities and interval measurements, and vital sign measurements will be used to assess this outcome measure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Cross-Over Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-Over Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5737</intervention_name>
    <description>A single dose of GS-5737 in 2.8% saline</description>
    <arm_group_label>Cross-Over Sequence 1</arm_group_label>
    <arm_group_label>Cross-Over Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) from ≥ 19 to ≤ 30 kg/m2

          -  Normal ECG, with no history or evidence of myocardial infarction, QT prolongation, or
             ventricular arrhythmias

          -  Normal (or abnormal but not clinically significant) blood pressure (BP) and heart
             rate(HR)

          -  History of lifetime smoking &lt; 5 pack-years (ie, 1 pack per day x 1 year = 1
             pack-year)and non-smokers of at least 60 days duration prior to Screening

          -  Negative screening tests for drugs of abuse (including alcohol)

          -  Hepatitis B (HBV) surface antigen negative

          -  Hepatitis C (HCV) antibody negative

          -  HIV-1, 2 antibody negative

          -  Male subjects who are sexually active must be willing to use highly effective
             contraception from the Baseline Visit through completion of the study and continuing
             for at least 90 days from the date of the last dose of study drug

          -  Male subjects must refrain from sperm donation from the Baseline Visit through
             completion of the study and continuing for at least 90 days from the date of the last
             dose of study drug

          -  Females of childbearing potential must have a negative serum pregnancy test

          -  Females of childbearing potential must agree to utilize protocol recommended highly
             effective contraception methods from Screening throughout the duration of study
             treatment and for 30 days following the last dose of study drug

        Exclusion Criteria:

          -  Female subjects who are pregnant or lactating

          -  History of anaphylactic reaction to any drug

          -  Have previously participated in an investigational trial involving administration of
             any investigational compound within 30 days prior to the study drug dosing

          -  Presence or history of extrinsic allergy requiring treatment; hay fever is allowed
             unless it is active or has required treatment within the previous 2 months

          -  Have donated blood within 56 days of study dosing

          -  Presence or history of any pulmonary diseases (ie, asthma, emphysema, chronic
             bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF),
             bronchiectasis, interstitial lung disease)

          -  Major surgery within 6 months of Screening

          -  Experienced symptoms of recent acute upper or lower respiratory tract infection
             requiring treatment within the 2 weeks prior to Screening

          -  Have had any radiation in the past year that would cause the subject exceed
             recommended limits by participating in this study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bresnik, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory health</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

